SHANGHAI--(BUSINESS WIRE)--

With the launch of Chinas 12th Five-year Plan for the biomedical industry, Chinas antibody drugs development will usher in a golden era. According to prediction of askci.com, by 2015, Chinas antibody drugs industry will record a total revenue of over RMB 40 billion, among which monoclonal antibody drugs will contribute over RMB 18 billion.

Under policy supports, Chinas antibodies R&D technology is constantly improving, with cancer and immune diseases as its main subjects, while therapeutic monoclonal antibodies also gained much progress. In addition, the enterprises have attached long-term importance to improving the protein expression in pilot trial and elevating the level of industrialization.

The 2ndAntibody Engineering Summit 2012 will discuss the policies, market, and R&D technologies, as well as arrange a GMP training session to interpret the latest standards and a factory tour to learn about the current technologies.

TOPICS:

PAST CHAIRMAN:

Ya-Jun Guo, Director of PLA General Hospital Cancer Center, Director of Cancer Research Institute of the Second Military Medical University and Chairman of National Engineering Research Center of Antibody Medicine and National Key Laboratory of Antibody Therapeutics.

PAST SPEAKERS/ATTENDEES:

ABOUT CBI

The medical conference team at CBI has long been committed to tracking the development and trend of medical industry, by adhering to the CBI principle of conducting in-depth study into the industry and keeping in close contact with industry players. The team takes a third-party perspective and regularly organizes summits on industrial hot issues. The ultimate goal is to serve professionals in the medical community by enhancing mutual understanding among domestic and overseas players, and by facilitating communication among research institutes, manufacturing enterprises and government institutions.

Read more:
2nd Antibody Engineering Summit 2012 to Open in Beijing This June